{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032231","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-08-11T20:00:59+00:00","discovered_at":"2026-08-11T20:02:13.287425+00:00","generated_at":"2026-08-11T20:02:40.042956+00:00","sec_items":["5.02","5.07"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apogee stockholders approve AbbVie merger; advisory comp proposal fails","bullets":["Merger proposal approved: 46,508,107 for, 3,885 against, 14,261 abstentions, satisfying a closing condition.","Non-binding compensation proposal failed: 19,323,605 for vs 27,123,259 against; not a condition to close.","All seven directors (Henderson, McKenna, Bollinger, Fox, Jones, Kiselak, Shah) to resign effective at merger close.","Special meeting quorum: 46,526,253 shares (74.87% of 62,140,183 outstanding) present.","Apogee to become indirect wholly-owned subsidiary of AbbVie upon merger completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032231","json":"https://secwatch.observer/filing/0001140361-26-032231.json","markdown":"https://secwatch.observer/filing/0001140361-26-032231.md","text":"https://secwatch.observer/filing/0001140361-26-032231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126032231/0001140361-26-032231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126032231/ef20079870_form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:02:40.042956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}